Buxton Returns, but the Twins' Timing Problem Persists

Minnesota activated Byron Buxton off the injured list Thursday morning, clearing him to play in tonight's Field of Dreams contest against Philadelphia in Iowa. The 32-year-old outfielder missed 14 games nursing a right hip impingement—his second stint on the IL this season for the same injury after reaggravating it just one week following his July 20 activation. The Twins' decision to bring him back against a Phillies lineup says something about roster desperation: Minnesota trails Chicago by 3.5 games in the AL Central and clings to a half-game for the final wild-card spot.

Buxton's underlying numbers paint a stark picture of regression. He's batting .263 with 25 home runs across 82 games, respectable on the surface—but those surface metrics collapse when you separate his timeline. He hasn't homered since June 22. In the 18 days since returning from his first hip injury on July 20, he's managed a .160 average with zero extra-base hits. That's not a slump; that's a functional absence at the plate. The hip issue was supposed to be resolved. It clearly wasn't, and even though doctors cleared him, Buxton's performance suggests his body is still negotiating with the injury.

For bettors, this activation carries real but narrow consequences. Buxton's presence does add a body to Minnesota's lineup and offers a marginal boost to team total projections—but only if he performs, and the evidence over the last three weeks suggests that assumption is fragile. The Twins' win probability shifted modestly upward with his activation, but the Field of Dreams game itself is a neutral-to-slight-Phillies situation (Philadelphia ranked 8th in team ERA entering Thursday; Minnesota's offense has produced just 3.2 runs per game over their last 15 contests). Buxton's individual props—hits, RBIs, home runs—should be faded or avoided entirely until he produces at least one game of competence at the plate. His 24-hour activation window doesn't erase six weeks of non-production. The line market has already priced in the roster addition; the edge belongs to anyone shorting his counting-stat confidence in a 1-game sample against a decent pitcher.